A nationwide cohort study of intravitreal aflibercept versus ranibizumab
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
Most Recent Events
- 01 Feb 2022 New trial record
- 22 Jan 2022 Results published in the Ophthalmology and Therapy